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We prepared an a-bungarotoxin-specific monoclonal antibody that neutralizes the biological activity of the toxin in vivo. 
The antigenic determinant combining specifically with this antibody was determined on the basis of cross-reaction experi- 
ments using three other long neurotoxins and peptide fragments of a-bungarotoxin. The antigenic determinant was locat- 
ed on the peptide fragment containing S34-S35-R36-G37-K38, which forms a part of the expected site that binds to the 
acetylcholine receptor proteins 
Monoclonal antibody; Bungarotoxin, a-; Antigenic determinant 
1. INTRODUCTION 
Neurotoxins isolated from the venom of 
Elapidae and Hydrophiidae families are immuno- 
genic polypeptides with three or four antigenic 
determinants imultaneously accessible to specific 
antibodies [1,2]. Because the neurotoxicity can be 
neutralized by specific antibody, work on the iden- 
tification of these antigenic determinants and 
elucidation of the molecular mechanism of this 
specific neutralization are practically important. 
a-Bungarotoxin (LYBTx) isolated from the venom 
of Bungarus multicinctus is a long cy-neurotoxin. 
The primary structure of cu-BTx was determined 
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[3-51. The crystalline and solution structures have 
also been extensively well defined [6-L?], so that cy- 
BTx is a good model to investigate the interaction 
between the antigenic determinant and the anti- 
body. Recently, Chuang and Chang reported the 
antigenic determinants of cu-BTx using polyclonal 
antibodies and peptide fragments [9]. However, in 
general, due to the heterogeneity of polyclonal an- 
tibodies, quantitative evaluation of the degree of 
cross-reactivity is not easy. So, it would be par- 
ticularly suitable to use a monoclonal antibody 
[lo]. In the present study, a monoclonal antibody 
specific for cu-BTx was prepared. The antigenic 
determinant specific to this antibody (MaB-23 11) 
was specified on the basis of the comparative cross- 
reactivity to homologous neurotoxins and peptide 
fragments obtained from limited proteolysis of CY- 
BTx. The antigenic determinant was located on a 
peptide fragment containing S34-S35-R36-G37- 
K38 which forms a part of the expected site that 
binds to the acetylcholine receptor proteins. 
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2. MATERIALS AND METHODS 
2.1. Materials 
Lyophilized venom of Bungarus multicinctus was purchased 
from Miami Serpentarium Laboratories. ‘251-labeled cr-BTx 
(1.8 mCi/mg) was obtained from ICN Radiochemicals. Male 
BALB/c and ddY mice were purchased from Shisuoka Agri- 
culture Cooperative Association for Laboratory Animals. (Y- 
BTx and toxin B (TX B) were purified from the venoms of 
Bungarus multicinctus and Naja naja, respectively. Toxin III 
(TX III) (Naja naja siamensis) and Ls III (Laticauda semi- 
fasciata) were kind gifts from Professors R.C. Hider (University 
of London) and N. Tamiya (Tohoku University), respectively. 
2.2. Preparation of monoclonal antibody 
Immunization of BALB/c mice (I-week-old) was achieved by 
subcutaneous injection of 2, 4, 8, and 10 rg of a-BTx (LDso: 
about 5 /g/mouse) at intervals of 2, 3, and 5 weeks in in- 
complete Freund’s adjuvant (0.1 ml). Two weeks after the last 
injection, 5 pg of a-bungarotoxin in physiological saline 
(0.2 ml) was injected intraperitoneally. Four days after the fifth 
injection, the spleens of two mice were removed. Spleen cells 
were combined with myeloma cells (NSI/l. Ag 4.1) in a ratio of 
1:4 and fused with poly(ethylene glycol) according to the 
method of GalfrC and Milstein [ll], using RPMI-1640 medium. 
Fused cells were plated in HAT medium (2 x lo5 cells/well) into 
460 wells (0.2 ml/well) of 96-well microtiter plates. Three weeks 
later, culture supernatants were screened for binding cu-BTx by 
an antigen-solid-phase enzyme-linked immunoassay. Bound an- 
tibodies were detected by addition of the immunoglobulin G 
fraction of peroxidase-conjugated goat anti-mouse immuno- 
globulins (Cappel). From 9 positive wells, two representative 
wells were selected and cloned three times. One of the two lines, 
designated MaB-2311 was chosen for amplification in ascitic 
fluid. Monoclonal hybridoma cells (1 x 10’) were injected intra- 
peritoneally into one BALB/c mouse prestimulated with 0.5 ml 
of 2,6,10,15-tetramethylpentadecane. O  week after inocula- 
tion, the mouse was killed and the ascitic fluid was removed and 
centrifuged (250 x g) for 10 min at 4°C. The cell precipitate was 
suspended and injected into 10 mice for the next inoculation, 
which was the same as described above. Sequential inoculations 
were repeated several times. 
Monoclonal antibody MaB-23 11 was partially purified from 
ascites fluid supernatant (10 mice) by ammonium sulfate (33% 
saturation) and Q Sepharose column chromatography and 
purification was completed by using an cu-BTx-conjugated Affi- 
gel 10 (Bio-Rad) column (2 ml). The yield of the purified anti- 
body was l-l .5 mg/ml of ascitic fluid. Purity of MaB-23 11 was 
assessed by SDS-polyacrylamide gel electrophoresis employing 
10% gels. The class of MaB-2311 was determined to be IgGi. 
2.3. Binding assay 
Radiobinding assays were performed according to the pro- 
cedure of Boulain et al. [lo], with minor modifications. 
Dissociation constant was determined by incubation at 4°C for 
18 h of 3 nM monoclonal antibody with iZ51-labeled a-bungaro- 
toxin (0.8-4 nM) in 0.2 ml of 50 mM sodium phosphate buffer 
(pH 7) containing 0.45% NaCl and bovine serum albumin 
(2 mg/ml). After incubation, 0.04 ml of bovine y-globulin frac- 
tion 2 (25 mg/ml, Miles Laboratories Inc.) was added to the 
reaction mixture, then, 0.4 ml of 20% (w/v) poly(ethylene 
glycol) 6000 (BDH Chemicals) was added to precipitate the im- 
munocomplexes. The reaction mixture was stirred and cen- 
trifuged (1500 x g) at 4°C for 30 min, and the radioactivity of 
the pellets was then counted. 
In cross-reaction experiments, 6 nM monoclonal antibody 
was incubated with 6.5 nM 1251-labeled a-bungarotoxin and 
various amounts of long neurotoxins or peptide fragments from 
cY-bungarotoxin. Each sample was treated as described above. 
2.4. Fragmentation of cu-bungarotoxin 
Enzymatic hydrolysis of reduced and carboxymethylated cy- 
bungarotoxin with lysyl endopeptidase was carried out by the 
method of Ohta et al. [4]. The peptide fragments were separated 
by reverse-phase high-performance liquid chromatography on a 
TSK-GEL ODS-12OT (Toy0 Soda) column (4.6 mm x 15 cm) 
with a linear gradient from 0 to 30% acetonitrile containing 
0.1% (v/v) trifluoroacetic acid. 
3. RESULTS 
3.1. Neutralization of a-BTx by MaB-2311 
The effect of monoclonal antibody MaB-23 11 on 
the lethality of mu-BTx was studied in vivo. 10 pg of 
cu-BTx, corresponding to a 100% lethal dose, was 
intraperitoneally injected into mice in the presence 
or absence of MaB-23 11, which corresponds to a 
100% lethal dose. The mean time until death in the 
absence of MaB-23 11 was 37 min. However, when 
we injected mixed solutions of a-BTx and 
MaB-2311 into two groups of mice with molar 
ratios (a-BTx/MaB-2311) of 1: 1 (group A) and 
1: 5 (group B), the mean times before death for 
both groups were significantly prolonged to 160 
and 500 min, respectively, showing that MaB-23 11 
actually neutralizes the lethal effects of a-BTx. 
When we compared the mice in the two groups, the 
mice in group A were already dead 200 min after 
injection, while the mice in group B only showed 
the initial clinical symptoms of a-BTx poisoning. 
Thus, the effect of MaB-2311 on the CPBTX- 
injected mice does not only prolong the mean time 
until death but also delays the whole process 
leading to death. 
3.2. Localization of the antigenic determinant 
recognized by MaB-2311 
Localization of the antigenic determinant was 
studied on the basis of cross-reaction experiments 
using MaB-23 11 as antibody, ‘251-labeled CY-BTx as 
the radioactive antigen and four kinds of unlabeled 
long neurotoxins - CPBTX, TX B, TX III, and Ls III 
- as competitors. The primary structures of these 
long neurotoxins are shown in table 1. Inhibition of 
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Table 1 
Primary structures of a-bungarotoxin (cu-BTx), toxin B (TX B), 
toxin III (TX III) and Ls III 
-BTx : IVCHTTAT SPISAVTCPPGENLCYRK~WCOAFCSSRGKVVELGCAATCPSI:KPYEEVTCCSTDKCNPHPKQRPG 
TX B : IRCF ITP DITSWCPNGH V‘YTKTWCDGFCSSRGKRVOLGCAATCPTVRTGWIBCCSTDOCOPFPTRKRP 
TX Ii, : lRCF ITP DlTSKDCPNGH VCVTKTWCDAFCSIAGKRVDtGCAAT‘PNKTGVDIOCCS~NCNPFPTRKRP 
LS III : RECY LNP HDT gTCPSGPElCYVKSWCNAWCSSRGKVtEFGCAATCPSYNTGTE,KCCSADKCNTYP 
the binding of 1251-labeled a-BTx to MaB-23 11 by 
unlabeled wBTx, TX B, TX III, and Ls III is 
shown in fig.1. Inhibition capacity of MaB-2311 
followed the order of cu-BTx>Tx B > Ls III with 
ICsO of 8 nM, 100 nM and 3 ,uM, respectively. 
However, in spite of the high homology between 
the primary structures of TX B and TX III, the lat- 
ter did not show any competition. Both toxins con- 
tain 71 amino acid residues and only 5 amino acid 
residues of G32, S34, R53, D66 and D67 in TX B 
are replaced by A32, 134, K53, N66 and N67 in 
TX III. The primary structures of these long neuro- 
toxins were compared [12,13] on the basis of the 
present results of the cross-reactivity experiments. 
The amino acid sequence common to cr-BTx, TX B, 
and Ls III was found to be C33-S34-S35-R36-G37- 
K38. However, in TX III, S35 is replaced by 135. 
Thus, we concluded that the antigenic determinant 
recognized specifically by MaB-23 11 is localized in 
the amino acid sequence around S35. This se- 
quence is located on the top of the central loop and 
is expected to be involved in the receptor binding. 
It is also to be noted that there is a disulfide bridge 
between C29 and C33 that may give a specific con- 
formation around this segment. 
I \ 
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Fig. 1. Binding of ‘*’ I- labeled a-bungarotoxin (cu-BTx) to mono- 
clonal antibody MaB-2311 in the presence of varying amounts 
of unlabeled cr-bungarotoxin (cu-BTx), toxin B (TX B), toxin III 
(TX III) or Ls III. In these experiments, 6 nM monoclonal anti- 
body was incubated with 6.5 nM ‘2sI-labeled a-bungarotoxin 
and varying amounts of long neurotoxins. 
3.3. Cross-reactivity of peptide fragments of 
a-BTx 
In order to elucidate the effect of the disulfide 
bridge on the binding of cu-BTx to MaB-23 11, we 
studied the cross-reactivities of the reduced and 
carboxymethylated cu-BTx (RCM cu-BTx) and its 
peptide fragments. The peptide fragments shown 
in table 2 were prepared by the limited proteolysis 
of RCM a-BTx using lysylendopeptidase after the 
method by Ohta et al. [4]. Cross-reactivities of 
RCM WBTX and the peptide fragments were 
studied in a similar manner as used for long neuro- 
toxins. RCM a-BTx and the peptide fragment L-5 
showed similar inhibition of binding between 1251- 
labeled WBTX and antibody, and their I& values 
were found to be 80 PM and 160 PM, respectively, 
while, no competition was found with other five 
peptide fragments (fig.2). Since RCM a-BTx and 
L-5 showed cross-reactivity, the disulfide bridge 
between C29 and C33 is not essential for the bind- 
Table 2 
Probable sequences of peptides from the proteolytic digestion of cu-bungarotoxin with lysylendopeptidase 
Peptide Amino acid sequence 
L-l (71-74) Q-R-P-G 
L-2 (65-70) C-N-P-H-P-K 
L3- (52-64) K-P-Y-E-E-V-T-C-C-S-T-D-K 
L-4 (39-5 1) V-V-E-t-G-C-A-A-T-C-P-S-K 
L-5 (27-38) M-W-C-D-A-F-C-S-S-R-G-K 
L-6 ( l-26) I-V-C-H-T-T-A-T-S-P-I-S-A-V-T-C-P-P-G-E-N-L-C-Y-R-K 
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Fig.2. Binding of lZsI-labeled u-bungarotoxin to monoclonal 
antibody MaB-2311 in the presence of varying amounts of 
reduced and carboxymethylated a-bungarotoxin and its peptide 
fragments. The sequence of each peptide fragment is shown in 
table 2. 
ing to MaB-23 11. Thus, we reached the conclusion 
that the antigenic determinant recognized by 
MaB-23 11 is S34-S35-R36-G37-K38. 
4. DISCUSSIONS 
This is the first report on the preparation of a 
monoclonal antibody specific for a-BTx. From the 
present study, monoclonal antibody MaB-23 11 was 
found to neutralize the toxicity of CPBTX and other 
long neurotoxins by specific binding to the anti- 
genie determinant of S34-S35-R36-G37-K38. Using 
polyclonal antibodies and peptide fragments, 
Chuang and Chang recently reported that four an- 
tigenic determinants were located on cu-BTx [9]. 
One of the antigenic determinants was located 
around residues 34-41. The antigenic determinant 
elucudated in the present study was restricted to a 
narrower range, to residues 34-38. Moreover, 
MaB-23 11 was found to bind to long neurotoxins 
with the sequence of S34-S35-R36-G37-K38 but not 
to those with the sequence of S34-135R36-G37- 
K38. This means that S35 is mainly responsible for 
the binding specified by MaB-23 11. The crystalline 
and solution structures of long neurotoxins 
elucidated by X-ray and NMR analysis are com- 
posed of three polypeptide loops that are shown in 
fig.3 [6-81. A three-stranded antiparallel-pleatedfl- 
sheet structure is formed by the central and the 
Fig.3. Location of the antigenic determinant recognized by 
MaB-2311 on the schematic structure of cu-bungarotoxin 
elucidated by X-ray and NMR analyses [6-g]. 
b- COOH 
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third loops, and is expected to be common to all 
neurotoxins. The antigenic determinant is located 
around the top of the central loop (fig.3). On the 
basis of the sequence homology and chemical 
modification studies, the side chains of the amino 
acid residues located on one surface of the three- 
stranded antiparallel-pleated P-sheet structure are 
suggested to be essential for neurotoxicity [ 12,131. 
These include K27, W29, D3 1, R36, and K47. Since 
R36 is involved in the region of the antigenic deter- 
minant recognized by MaB-23 11, neutralization of 
toxicity by MaB-23 11 is induced by the direct bind- 
ing of MaB-2311 to the toxic region. However, it 
should be noted that the side chain of S35 is located 
on the opposite surface of this P-sheet structure. 
Thus, MaB-2311 may bind to the region from the 
back of the toxic surface and induce a conforma- 
tional change that inhibits the binding of toxins to 
the receptor proteins. 
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